Status:
COMPLETED
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Lead Sponsor:
CSL Behring
Conditions:
Immune Thrombocytopenic Purpura
Eligibility:
All Genders
12-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter i...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of chronic ITP defined by: Failure to find other causes of thrombocytopenia; Platelet count ≤ 150 x 10\^9/L over 6 months or response to a previous treatment with subsequent decrease in platelet count even if duration of chronic ITP is less than 6 months
- Platelet counts ≤ 20 x 10\^9/L
- Key
Exclusion
- Planned splenectomy throughout the study period
- Treatment with IVIG or anti-D immunoglobulin within 3 weeks prior to screening
- Treatment with immunosuppressive or other immunomodulatory drugs within 3 weeks prior to screening
- Treatment with intravenous steroids within 10 days prior to screening
- Change of oral steroid treatment within 15 days prior to screening
- Patients with known or suspected hypersensitivity to immunoglobulins or previous severe side effects to immunoglobulin therapy
- Abnormal results in the following laboratory parameters: Hemoglobin \< 10 g/dL; Total bilirubin \> 1.5 x upper normal limit; ALAT \> 2.5 x upper normal limit; ASAT \> 2.5 x upper normal limit; Creatinine \> 1.5 x upper normal limit; Urea \> 1.5 x upper normal limit
- Positive direct Coombs test
- Patients with one of the following concomitant diseases Clinical active SLE Known or suspected HIV infection Acute hepatitis Clinically active chronic hepatitis Lymphoproliferative disease Heart failure Grade III or IV according to the New York Heart Association classification
- Any other concomitant disease that has influence on the clotting system (i.e. hemophilia)
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00168038
Start Date
December 1 2004
End Date
February 1 2006
Last Update
November 23 2011
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Study Site
Berlin, Germany
2
Study Site
Rome, Italy
3
Study Site
Bialystok, Poland
4
Study Site
Gdansk, Poland